Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1Phase 2 1Phase 1 1

Status

Completed 24Active not recruiting 7Terminated 6Recruiting 5

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 34Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Squamous Cell Carcinoma of Head and Neck 23Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 13Uterine Cervical Neoplasms 12Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Lung Diseases 5Adenocarcinoma of Lung 5Thoracic Neoplasms 4

Interventions

pembrolizumab 20Gemcitabine 18Cisplatin 14Magnetic Resonance Spectroscopy 13enfortumab vedotin 12Specimen Handling 10Cystectomy 10Docetaxel 8Mitomycin 7Standard of Care 6Cystoscopy 6Transurethral Resection of Bladder 5Radiotherapy 5Carboplatin 5durvalumab 4Practice Guidelines as Topic 4Nivolumab 4Radiation 3Multiparametric Magnetic Resonance Imaging 3Mitozytrex 3Fluorouracil 3tislelizumab 2dehydroftorafur 2cemiplimab 2avelumab 2alvimopan 2Therapeutics 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Urinary Bladder Neoplasms × Carboplatin × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 1 Recruiting
1,006 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04574960 2025-07-20

NAUTICAL

University Health Network, Toronto

Phase 3 Recruiting
14 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
63 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡